pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,109 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints892BioPharma Dive343BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7585Rare Disease1872Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • Roche to acquire PathAI for $750 million to boost AI pathology
    Roche announced it will acquire Boston based PathAI for an upfront payment of $750 million. The acquisition follows a partnership that began in 2021 and is intended to speed the use of artificial i…
    STAT · 4mo agoDealPositive↗ source
  • Lilly adds $4.5 billion to Indiana manufacturing to boost weight-loss drug supply
    Eli Lilly & Co. announced an additional $4.5 billion investment in two of its three manufacturing sites in Lebanon, Indiana. The funding is aimed at expanding capacity for both its genetic therapie…
    BioPharma Dive · 4mo agoDealPositive↗ source
← prev
page 111 of 125
next →
fda recalls69
fda medwatch60
fda press38
1172
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
  • Former FDA officials and pharma groups weigh in as Supreme Court considers mifepristone regulation
    The Supreme Court is expected to act on a case involving the abortion pill mifepristone after a pause on a federal appeals court order that halted mail‑order distribution. The decision could resha…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Trump reportedly plans to dismiss FDA Commissioner Marty Makary
    Multiple media outlets report that President Donald Trump is considering removing FDA Commissioner Marty Makary from his post. The reports say the decision has not been finalized and could still be…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • WSJ reports Trump plans to fire FDA Commissioner Marty Makary, decision not yet final
    The Wall Street Journal reported that President Donald Trump is considering removing FDA Commissioner Marty Makary from his post. The report said the administration has not yet made a final decisi…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Daiichi Sankyo writes off $950 million after abandoning ADC manufacturing plan
    Daiichi Sankyo announced it will abandon its planned antibody-drug conjugate (ADC) manufacturing facility. The company said the decision follows a serious over-estimate of third-party demand for AD…
    Endpoints · 4mo agoEarningsNegative↗ source
  • FDA pushes Leqembi subcutaneous decision to Aug. 24; Artiva secures $300M and Pharvaris sets pricing
    The U.S. Food and Drug Administration has postponed its review of the subcutaneous formulation of Leqembi. The original target date earlier this month has been moved to August 24, as Biogen and Eis…
    Endpoints · 4mo agoRegulatoryNeutral↗ source
  • Trump reportedly moves to dismiss FDA Commissioner Marty Makary
    President Trump is said to have approved a plan to remove FDA Commissioner Marty Makany, according to several news outlets. The proposed ouster would add to recent turnover in the agency’s senior l…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Capricor sues Nippon Shinyaku over delayed Duchenne drug rollout and pricing formula flaw
    Capricor Therapeutics has filed a lawsuit in New Jersey alleging that Nippon Shinyaku and its US subsidiary NS Pharma have failed to execute agreed upon marketing plans for the company's Duchenne m…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Spain prepares to isolate over 140 cruise passengers amid hantavirus outbreak
    Spanish authorities are ready to receive more than 140 passengers and crew from a cruise ship flagged with a hantavirus outbreak as it approaches Tenerife. The vessel is expected to dock on Sunday…
    STAT · 4mo agoNegative↗ source
  • Epidemiologist highlights surge of hantavirus misinformation after cruise ship outbreak
    An outbreak of hantavirus tied to the cruise ship MV Hondius has generated serious health concerns, but online discussion has taken a different turn. Social media users quickly began sharing false…
    STAT · 4mo agoPositive↗ source
  • Immunic appoints Michael Panzara as chief medical officer, coming from Neurvati Neurosciences
    STAT+ columnist Ed Silverman's weekly feature highlights recent personnel changes in pharma. This edition notes a new appointment at Immunic. Immunic has named Michael Panzara its new chief medica…
    STAT · 4mo agoNeutral↗ source
  • The biotechs wear Prada
    Was Naomi Osaka's Met Gala outfit inspired by Gilead's logo? Janelle Monáe's by Insilico's? Probably not — and yet.
    STAT · 4mo ago↗ source
  • FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
    Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: The biotech news you need to read today
    A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
    STAT · 4mo ago↗ source
  • Lilly, Gilead lead pharma’s M&A boom
    Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and more
    An FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on research
    STAT · 4mo ago↗ source
  • 'Pharma, not really’: Top young AI talent shuns careers at big drugmakers
    RIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medical…
    Endpoints · 4mo ago↗ source
  • The aging scientific workforce collides with rising fabricating citations in medical journals
    The latest in the hantavirus cruise ship saga, why these former officials left the FDA, and more health news from Morning Rounds
    STAT · 4mo ago↗ source
  • Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech
    → It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of ...
    Endpoints · 4mo ago↗ source
  • Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep
    Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…
    Endpoints · 4mo ago↗ source
  • Opinion: We need more men in nursing
    Men make up just 12% of nurses nationally. That needs to change.
    STAT · 4mo ago↗ source
  • Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
    “The pediatric and orphan pipeline is already the smallest, slowest, and least capitalized segment of the device industry,” writes Kolaleh Eskandanian.
    STAT · 4mo ago↗ source
  • Why we left the FDA: Six former officials share their stories
    In this week's STATus Report, hear from six former FDA officials on why they left the agency.
    STAT · 4mo ago↗ source
  • Odyssey raises more than $300M as biotech goes public
    Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The bio…
    Endpoints · 4mo ago↗ source